Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
BRANFORD, Conn., Jan. 21, 2016 -- BioXcel Corporation, a global leader in cloud-based big data platforms and developer of transformative patient treatments, today announced the launch of its first in class PharmGPS® Oncology and Immuno-Oncology Suite. The platform’s comprehensive big data approach provides industry stakeholders with actionable intelligence to empower the selection, prioritization, identification and development of promising immunotherapies across the broad oncology spectrum.
“We have reached an exciting inflection point in our integrated discovery ecosystem where the application of our big data technology enables the identification of therapeutic candidates with the highest probability of success to create tangible value for our partners and potentially change the cancer treatment paradigm,” said BioXcel’s President and Chief Scientific Officer, Krishnan Nandabalan, Ph.D. “This platform is designed to overcome the key challenges faced by oncologists and patients by creating potentially disruptive therapies in a rational and highly efficient manner.”
With the PharmGPS® Oncology and Immuno-Oncology Suite, partners are able to optimize their portfolios and pipeline assets by identifying and prioritizing mono- and combination therapies that have the greatest potential to improve patient outcomes for specific tumor types. The Oncology and Immuno-Oncology suite currently spans over 40 different tumors, 484 unique drugs and combinations, 115 validated drugs and novel targets along with multiple modalities including targeted therapies, immunotherapies, vaccines and cellular therapies. The user-friendly interface allows for an in-depth overview of the immuno-oncology landscape, target-drug-pathway-indication networks and scenario analyses of potential therapeutic outcomes using immunotherapies in cancer.
"Our first-of-its-kind big data analytics platform is integrating and expanding upon decades of knowledge in the oncology space to drive therapeutic innovation and improve patient outcomes. We believe that PharmGPS® Oncology and Immuno-Oncology Suite has the potential to become an indispensable tool for our biopharma customers and partners, and a critical asset for BioXcel as we build our own portfolio of oncology assets,” said BioXcel’s Vice President, Oncology R&D, Luca Rastelli, Ph.D.
The company will be showcasing its platform at Phacilitate's Immunotherapy World Forum conference in Washington D.C on January 25th- 27th.
PharmGPS® Oncology and Immuno-Oncology Suite
A live and multi-dimensional platform, BioXcel's proprietary suite enables the extensive analysis of tumors and the impact of constituent global drug pipelines and benchmarking, novel drug targets and therapeutic approaches, including the inhibition of immune checkpoints, on standards of care and lines of therapies. All key drivers necessary for designing the most optimal combination therapies, clinical trial design and positioning of the right anti-cancer agents are taken into account to maximize market share and most importantly benefit to the patient. Furthermore, the suite is comprehensive in assessing all modalities, combinations of therapies and different stages of development. This extensive analysis delineates an optimal path with respect to indication segment relevance, best-fit therapies, and target effectiveness compared to the most relevant standard of care.
About BioXcel
BioXcel is a global leader in providing cloud-based Pharma big data solutions for discovering novel products and performance benchmarking of pipeline innovation and marketed products in all major therapeutic areas. Our first in class Big Data Innovation Lab is focused on the development of transformative patient treatments for strategic portfolio growth and leverages; PharmGPS® - a live analytics platform; an Integrated Center of Xcellence housing multidisciplinary scientific, commercial and medical teams; and a drug development team that offers deep domain expertise. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.
CONTACT: BioXcel Corporation Anita Ganjoo Corporate Communications Email: [email protected] Tel: 203 957 2487
